Our site uses cookies. Learn more about our use of cookies: cookie policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content Skip to footer
Subscribe Now
News

Boehringer Ingelheim Enters a ~$573M Deal with Tessellate Bio to Develop Novel Therapies for ALT-positive tumors

Shots:

  • BI & Tessellate Bio have entered into a research collaboration & global license agreement to develop oral therapies for ALT-positive tumors
  • As per the terms, Tessellate Bio will receive near term payments incl. an upfront license fee, research funding & technical milestones along with downstream success-based milestones, making it an aggregate of ~$573M (~€500M)
  • Collaboration will focus on developing oral precision therapies for ALT-positive tumors, where blocking the target induces DNA damage, replication stress, & selective tumor cell death in ALT-positive cells

Ref: Boehringer Ingelheim | Image: BI & Tessellate Bio

Related News:- Cue Biopharma Collaborates with Boehringer Ingelheim to Develop B cell-Targeting Bispecifics for Autoimmune and Inflammatory Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Tags:
Share Post

You May Also Like

GSK
March 3, 2025
GSK Presents Pooled Analysis from P-III (ANCHOR-1 & 2) Trial of Depemokimab for CRSwNP at AAAAI/WAO Joint Congress 2025
Abbvie
February 28, 2025
The CHMP Adopts Positive Opinion for AbbVie’s Rinvoq (Upadacitinib) to Treat Giant Cell Arteritis in Adults
Ceribell
April 17, 2025
Ceribell’s Clarity Algorithm Receives the US FDA’s 510(k) Clearance to Detect Electrographic Seizures in Pediatric Patients

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]